ContactDictionary

Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  venetoclax
Find trials that include:  Any drugs shown
Results 1-16 of 16 for your search:
Start Over
A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 to 99
Trial IDs: M14-031, NCI-2016-01807, 2015-004411-20, NCT02755597
A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: M15-656, NCI-2017-00774, 2016-001466-28, NCT02993523
A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 60 and over
Trial IDs: GH29914, NCI-2016-00260, 2015-003386-28, NCT02670044
Venetoclax in Treating Patients with Relapsed or Refractory Waldenstrom Macroglobulinemia
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 15-491, NCI-2016-00699, NCT02677324
Venetoclax and Ibrutinib in Treating Patients with Chronic or Small Lymphocytic Leukemia
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2015-0860, NCI-2016-00797, NCT02756897
Ibrutinib Plus Venetoclax in Patients With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 to 69
Trial IDs: PCYC-1142-CA, NCI-2016-01487, NCT02910583
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 to 99
Trial IDs: M15-538, NCI-2016-01672, NCT02899052
A Study Evaluating Venetoclax in Combination With Azacitidine Compared With Azacitidine Alone in Participants With Previously Untreated Higher-Risk Myelodysplastic Syndromes (MDS)
Status: Temporarily closed
Phase: Phase II
Type: Treatment
Age: 18 to 99
Trial IDs: M15-531, NCI-2016-01891, 2016-001657-41, NCT02942290
Venetoclax, Rituximab, and Combination Chemotherapy in Treating Patients with Richter Syndrome
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 16-596, NCI-2017-00489, NCT03054896
A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GO28440, NCI-2013-01974, 2012-002351-42, NCT01671904
Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo)
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 65 and over
Trial IDs: M14-358, NCI-2014-01763, 2014-000687-18, NCT02203773
A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GO29833, NCI-2015-02093, 2015-001998-40, NCT02611323
Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: OSU-16187, NCI-2016-01723, 2016C0150, NCT02992522
A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 to 99
Trial IDs: M15-522, NCI-2017-00277, 2016-001904-46, NCT02966782
Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and 80
Trial IDs: 1607017413, NCI-2017-00395, NCT03036904
Venetoclax and Cytarabine with or without Idarubicin Hydrochloride in Treating Pediatric Patients with Refractory or Relapsed Acute Myeloid Leukemia
Status: Active
Phase: Phase I
Type: Treatment
Age: 24 and under
Trial IDs: VENAML, NCI-2017-01129, NCT03194932
Start Over